- TLDR Biotech
- Archive
- Page 3
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | March 5 - 6, 2025
UK's NICE rejects Biogen/Eisai's Leqembi and Eli Lilly's Kisunla for Alzheimer's disease, Neurotech nabs FDA approval for encapsulated cell therapy for macular telangiectasia type 2, Frazier Life Sciences raising new venture fund (XII), federal court approves $700M settlement from various drug companies to 1,000+ hospitals over opioid misconduct allegations, Novo Nordisk to investigate potential of GLP-1 drugs in treating addiction + 29 more stories
Biotech & Pharma Updates | March 4 - 5, 2025
Eli Lilly opens web portal to accept applications for potential US sites as part of $27B investments, Jazz Pharma acquires Chimerix for $935M to gain promising rare brain tumor therapy, Novo Nordisk drops Wegovy's price by 23% to $499 monthly for uninsured patients, BioNTech's mRNA malaria vaccine slapped with FDA clinical hold, CDC boots hit the ground in Texas to assist with growing measles outbreak + 33 more stories
Biotech & Pharma Updates | March 3 - 4, 2025
Illumina sequencers hit with Chinese import ban, Sofinnova Partners raises a €1.2B ($1.3B) healthcare VC fund, BeiGene's PD-1 inhibitor Tevimbra lands another FDA-approved label in first-line esophageal squamous cell carcinoma, Evotec nabs $20M payment as part of neuroscience collab with BMS, DOGE cuts leases for 30 FDA facilities across 23 states + 29 more stories
Biotech & Pharma Updates | March 2 - 3, 2025
AbbVie finally joins the obesity foray (paying Gubra $350M upfront), Novo Nordisk & Gensaic partner to development cardiometabolic therapies using AI-enabled FORGE technology, Callio Therapeutics launches with a $187M Series A and multi-payload ADC aspirations to fight cancer, Lexicon pushes ahead with pilavapadin Ph3 despite failing in Ph2b, top HHS spokesperson abrupt resignation after alleged clashes with RFK Jr. + 28 more stories
Biotech & Pharma Updates | February 27 - March 2, 2025
Eli Lilly signs molecular glue discovery partnership with Magnet Biomedicine, Eisai out-licences FGFR2-targeting tasurgratinib Greater China rights to SciClone, Merck & Co. offered $30M facility build grant by Delaware government, BMS cuts 223 more staff in New Jersey as part of cost-cutting drive, Infectious disease experts plan independent vaccine advisory group pre-empting “eroding” of said committees by RFK Jr. + 26 more stories
Biotech & Pharma Updates | February 26 - 27, 2025
Vertex Pharmaceuticals & Verve Therapeutics end liver disease gene editing collab, BeiGene's BTK inhibitor surpasses AstraZeneca's BTK inhibitor in quarterly sales, Medigene & EpimAb Biotherapeutics co-developing TCR-guided T cell engagers for solid tumors, big pharma players (Eli Lilly, Bristol Myers Squibb, Sanofi and Roche) defy Trump administration’s DEI stance by affirming commitment to diverse clinical trials, Regeneron abandons accelerated approval ambitions for bispecific odronextamab in B cell lymphoma + 31 more stories
Biotech & Pharma Updates | February 25 - 26, 2025
Eli Lilly commits a whopping $27B to build four new US production facilities, Eikon Therapeutics lands a $350.7M Series D to advance engineering + molecular biology driven drug discovery, HBM Alpha Therapeutics licenses CRH antibody therapy to undisclosed partner for up to $395M, AstraZeneca touts positive Ph3 data for camizestrant (estrogen receptor degrader) in certain forms of breast cancer, Idorsia hits dire funding straits as global rights sale of hypertension drug Tryvio falls through + 24 more stories
Biotech & Pharma Updates | February 24 - 25, 2025
Eli Lilly reduces Zepbound vial prices, Regeneron's genetic hearing loss gene therapy improves hearing in 12 pediatric patients, Castle Creek Biosciences $75M royalty financing from Ligand Pharmaceuticals, Takeda & BridGene Biosciences sign $770M small molecule drug discovery/design partnership using IMTAC platform to discovery/design partnership, J&J sues Samsung Bioepis over alleged unlawful Stelara biosimilar sublicensing agreement + 34 more stories
Biotech & Pharma Updates | February 23 - 24, 2025
Pfizer and Summit Therapeutics partner to test ivonescimab with Pfizer's ADCs in solid tumors, Amgen to invest $200 million in new Indian tech center focused on AI and data science for drug development, Hengrui Medicine's positive Ph3 data for CDK4/6 inhibitor + endocrine therapy in breast cancer, Entrada Therapeutics' exon 44 skipping therapy for Duchenne muscular dystrophy cleared FDA clinical hold, FDA declines to expand Invivyd's Pemgarda COVID-19 emergency use authorization + 25 more stories
Biotech & Pharma Updates | February 20 - 23, 2025
bluebird bio bought by PE for $29M (down from $10B valuation), FDA declares semaglutide shortage is over (good news for Novo Nordisk, bad news for compounders like Hims & Hers), Gilead's PPAR-delta agonist Livdelzi lands European approval for primary biliary cholangitis, Eli Lilly invest $500M+ into supply of yet-to-be-approved oral obesity pill orforglipron, Pfizer discontinues hemophilia B gene therapy Beqvez globally + 26 more stories
Biotech & Pharma Updates | February 19 - 20, 2025
BridgeBio reports strong initial demand for Attruby (outpacing investor expectations), Genmab's bispecific Epkinly nabs MHLW (Japan) approval for relapsed/refractory follicular lymphoma, EG 427's €27M ($28.4M) Series B to develop herpes virus-based gene therapy for bladder control in spinal injury patients, AstraZeneca acquires FibroGen's China operations for $160M, CDC delays first vaccine advisory committee meeting under new administration + 37 more stories
Biotech & Pharma Updates | February 18 - 19, 2025
Recursion-backed Altitude Labs launches pre-seed fund to help address funding gap caused by NIH cuts, CSPC Pharmaceutical out-licenses ROR1-targeting ADC to Radiance Biopharma for up to $1.2B, Cabaletta Bio's CD19-targeting CAR-T shows promise in lupus + dermatomyositis Ph1/2 trial, Merck & Co. & Epitopea partner to discover hidden tumor antigens, CRISPR gene-editing hopeful Spotlight Therapeutics shutters + 29 more stories